Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect
  • NCT03455452

Active, Not Recruiting

An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer - CA209-9GY

Aggiornato: 26 luglio, 2023   |   ClinicalTrials.gov

Stampa il riassunto

STAI PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampa questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il tuo medico
Utilizza la guida alla sperimentazione per esplorare il processo di partecipazione a una sperimentazione clinica. Cerca di comprendere i fattori chiave da considerare prima di decidere e pensa alle domande da porre al team di professionisti sanitari che sono coinvolti nella conduzione dello studio.
Stampa questa pagina CA209-9GY
Scarica la guida

SELEZIONI UNA LINGUA

Dettagli della sperimentazione

  • Sesso

  • 18+

    Fascia d'età

  • Active, Not Recruiting

Opzioni di trattamento

Bracci dello studio
TERAPIA ASSEGNATA
Cohort 2: Nivolumab + Ipilimumab
Renal Cell Carcinoma (RCC) Participants

Principali criteri di idoneità

Inclusion Criteria: - Adult patients with the diagnosis of advanced RCC (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab as second or third line therapy for the first time for the treatment of RCC, according to the label approved in France Exclusion Criteria: - Patients with a primary diagnosis of a cancer other than advanced RCC within the past five years, ie, a cancer other than RCC that requires systemic or other treatment - Patients previously treated with anti-PD1, anti-PDL1 or anti-CTLA4 therapy - Patients currently included in an interventional clinical trial for their advanced or RCC. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for OS can be enrolled Other protocol defined inclusion/exclusion criteria could apply

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche

Hai domande? Invia una e-mail

Hai domande?
Invia una e-mail